The sales of Calcium Channel Blocking medicines in Canada are forecasted to decline steadily from 2024 to 2028, starting at 296.8 million USD in 2024 and reducing to 283.0 million USD by 2028. Compared to their 2023 standing, this denotes a consistent year-on-year reduction in sales, reflecting a contracting market. The compound annual growth rate (CAGR) over these five years highlights this downward trend, with an average annual decrease in sales.

Future trends to watch for include:

Potential impact of new generic entrants reducing market value.
Shifts in healthcare policies affecting prescription practices in Canada.
Advancements in alternative cardiovascular therapies influencing calcium channel blockers usage.
Trends in patient demographics that might alter prescription patterns.